Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay Save Nov 09, 2021 4:20 pm Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting. ADD THE FIRST COMMENT If you are a health practitioner, you may Login/Register to comment.Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.